Optimistically, we further explored the role of NAF-1 as a novel molecular target for improving the efficacy of the currently used chemotherapeutic regimens in patients with pancreatic cancer and improving their clinical prognosis. This evidence concerns the gene NAF1 and familial pancreatic carcinoma.